📰 Planned Phase News
Planned Phase News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Planned Phase. Real-time updates on events, politics, business and more.
March 13, 2024
The Beauty Health Company (NASDAQ:SKIN) Q4 2023 Earnings Call Transcript March 12, 2024 The Beauty Health Company beats earnings expectations. Reported EPS is $-0.07, expectations were $-0.11. The Beauty Health Company isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good […]
December 7, 2023
Meeting Provided a Clear Path for Planned Phase 3b Trial NEW YORK, Dec. 7, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for...
May 31, 2023
Submitted a new drug application (NDA) for troriluzole in Spinocerebellar Ataxia Type 3 (SCA3) to U.S. FDA in 2Q2023, marking the teams fourth NDA in...
November 21, 2022
Plus Therapeutics Provides Updates on ReSPECT™ Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology - read this article along with other careers information, tips and advice on BioSpace
November 19, 2022
ReSPECT-GBM clinical trial of rhenium (186Re) obisbemeda in recurrent glioblastoma continues to demonstrate safety and overall survival correlates with...
November 2, 2022
Third-Quarter 2022 Results: -- Net Sales of $925.4 Million -- -- GAAP Net Income of $135.8 Million; Adjusted EBITDA of $335.3 Million, Which Includes $19.0 Million of Acquired IPR&D and Milestones
September 12, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
August 12, 2022
- Positive Data from the Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia Presented at European Hematology Association Meeting 2022 - - Positive Data from the Ongoing Phase 2 Study... | August 12, 2022
August 3, 2022
Second-Quarter 2022 Results:-- Net Sales of $876.4 Million; Orphan Segment Net Sales Increased 13% to $841.3 Million ---- GAAP Net Income of $61.0 Million; Adjusted EBITDA of $306.6 Million ---- TEPEZZA® (teprotumumab-trbw) Net Sales of $479.8 Million ---- KRYSTEXXA® (pegloticase injection) Net Sales of $167.8 Milli...
May 10, 2022
Planned Phase 1a Single Ascending Dose ("SAD") clinical trial of fezagepras expected to commence in Q2 2022Completion of analysis of safety and pharmacokinetic ("PK") data from Phase 1 Multiple